-
Haemophilia: Assessment of dental habits and oral health in children and adolescents with bleeding disorders
Time of Update: 2021-12-01
Evaluate the dental habits, needs, and oral health of pediatric patients with bleeding disorders, and determine predictors of poor oral health .
In summary, children with bleeding disorders usually have obvious dental lesions and report obstacles in dental care, posing a potential risk of disease .
-
Clin Cancer Res: Long-term prognosis of Tislelizumab in the treatment of relapsed/refractory classic Hodgkin's lymphoma
Time of Update: 2021-12-01
This article reports the results of a phase II clinical trial of Tislelizumab for the treatment of 70 patients with relapsed/refractory classic Hodgkin’s lymphoma and extended follow-up for 3 years .
Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis .
-
NEJM: AAV gene therapy for hemophilia, with significant effect and good safety
Time of Update: 2021-12-01
It is the ultimate goal of researchers to safely deliver coagulation factor VIII to patient cells through gene therapy, allow it to be stably expressed for a long time, and use a very low vector dose to improve the patient's bleeding and coagulation function .
-
Boshengji Pharmaceutical's CD7-targeted CAR-T cell injection obtained the U.S. FDA orphan drug designation
Time of Update: 2021-12-01
(hereinafter referred to as "Boshengji") announced its development of CD7-targeted chimeric antigen receptor (CAR)-T cell injection (PA3-17 injection) received US food and drug Administration Administration ( the FDA ) granted orphan drug qualification (orphan drug Designation, ODD), for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia / lymphoma (T-cell acute lymphoblastic leukemia / lymphoma (T-ALL/LBL)) .
-
HEMATOLOGICAL ONCOLOGY: Application of bronchoscopy to newly diagnosed patients with acute leukemia
Time of Update: 2021-12-01
Microbiology studies from BAL fluid and those obtained before bronchoscopy were classified as clinically significant or insignificant by retrospective infectious disease physicians (ML) .
-
J Clin Oncol: Bonatumumab non-response and high disease burden suggest that B-ALL patients with CD19-CAR treatment have a poor prognosis
Time of Update: 2021-12-01
Bonatumumab treatment non-response and high disease burden are independently related to poor RFS and EFS after CD19-CAR treatment in B-ALL patients .
Bonatumumab treatment non-response and high disease burden are independently related to poor RFS and EFS after CD19-CAR treatment in B-ALL patients .
-
2021 CSCO highlights you missed are all here~
Time of Update: 2021-11-16
2021 CSCO expert interview | Professor Zhang Yizhu: new progress in the treatment of lymphoma in children and adolescents 4.
2021 CSCO expert interview | Professor Deng Qi talks about the treatment progress of extramedullary multiple myeloma 6.
-
Nat Nanotechnol breakthrough!
Time of Update: 2021-11-16
On October 25, 2021, Ma Guanghui, Wei Wei, Martin of Peking University, and Yuhua Li of Southern Medical University from the Institute of Process Engineering of the Chinese Academy of Sciences published an online publication titled "Ferritin-based targeted delivery of arsenic to" in Nature Nanotechnology (IF=39).
-
Molecular Cancer Guangzhou Medical University Jiang Hua/Xu Ling found a new prognostic marker for acute myeloid leukemia in children
Time of Update: 2021-11-16
40) entitled "CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid Leukemia" research paper, which used circRNA microarray to study the expression pattern of circRNA in children with AML .
-
New cell immunotherapy——STAR-T for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia
Time of Update: 2021-11-16
In addition, in terms of proliferation ability, the proliferation of dual-target STAR-T cells in vivo is good, reaching a peak on the 10th day (7-14 days), and the number of copies in peripheral blood is 6.
-
Professor Song Yuqin: The new anti-CD20 monoclonal antibody otuzumab, innovative mechanism provides new treatment options for relapsed and refractory FL
Time of Update: 2021-11-16
The GADOLIN study shows that rituximab-resistant FL patients or relapsed after treatment, the use of otuzumab is still effective , And there is a survival benefit (compared with bendamustine single agent), which may be derived from the innovative mechanism of action of otuzumab .
-
Knowing Lymphology·Phase 2 Pathology Expert Talk: Combining Theory and Practice to Help Pathological Diagnosis of Lymphoma
Time of Update: 2021-11-16
Interview with Professor Xu Enwei (the video is longer, it is recommended to watch under WiFi conditions) What are the precautions for the differential diagnosis of common lymphoma and related lesions in the intestinal tract of Yimaitong?
-
[Nature Sub-Journal] A new method for treating leukemia!
Time of Update: 2021-11-16
Researchers at Bar-Ilan University in Israel have revealed a new treatment method against blood cancers developed by Professor Mira Barda-Saad of Mina and Everard Goodman School of Life Sciences and his research team, which involves attacking the cytoskeleton The protein WASp, which has a unique structure in active blood cancer cells .
-
One out of every eight people will get it. This disease has a new idea of diet therapy!
Time of Update: 2021-11-16
The research shows that regular consumption of millet can effectively prevent and reduce iron deficiency anemia .
Regular consumption of millet provides new ideas for the prevention and treatment of iron-deficiency anemia.
-
New treatment strategies for elderly patients with acute myeloid leukemia
Time of Update: 2021-11-16
The low-intensity dinucleoside analog combination regimen of Cladribine + low-dose cytarabine (LDAC) alternating AZA showed high CR rates and long-lasting OS in newly diagnosed patients with a median age of 69 years .
-
New target CD99 CAR-T for T-ALL releases research data
Time of Update: 2021-11-16
Recent popular reports from Yimaike ★The first cancer immunotherapy for adjuvant treatment of NSCLC was approved, reducing the risk of early lung cancer recurrence by 34% ★Wu Zhiwei/Liu Yalan team jointly developed inhaled new nanoantibodies to effectively inhibit new coronavirus infections October 26, 2021/Doctor EMedClub News/--Recently, Professor Zhang Tongcun of Wuhan Polytech Biosciences published a titled "CAR T cells targeting CD99 as" in the international authoritative journal "Journal of Hematology & Oncology" (IF 17.
-
STAMP inhibitor Asciminib is expected to bring good news to CML patients!
Time of Update: 2021-11-16
Yimaitong invited Professor Wang Jianxiang from the Hematology Hospital of the Chinese Academy of Medical Sciences to combine the results of the ASCEMBL Phase III clinical study on Asciminib in chronic myeloid leukemia (CML-CP) adult patients who have previously received two or more TKI treatments Application for wonderful interpretation and review!
-
Chinese scholars have developed a bionic delivery vector loaded with arsenic, which can significantly inhibit a variety of leukemias
Time of Update: 2021-11-16
The State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, based on ferritin particles (Fn) and the approved drug arsenic trioxide (ATO) in the body, proposed a new biomimetic delivery strategy and cooperated with Peking University and Zhujiang Hospital.
-
Correlation between intensity of treatment plan and prognosis in elderly patients with Hodgkin's lymphoma
Time of Update: 2021-11-16
A retrospective cohort study used the SEER-Medicare database to explore the relationship between the intensity of treatment options and the cause-specific mortality of elderly HL patients .
-
Professor Liang Aibin: New targeted drug selinexor brings new hope to DLBCL patients
Time of Update: 2021-11-16
Professor Liang Aibin, Doctoral Supervisor, Professor, Deputy Dean of Tongji Hospital, Director of Hematology Oncology Center, Deputy Secretary-General of the Experimental Hematology Committee of the
